Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (15434)
All Articles published online
|
Publishing Process of This Article
|
Dec 10, 2015 (publication date) through Nov 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yadav BS, Chanana P, Jhamb S. Biomarkers in triple negative breast cancer: A review. World J Clin Oncol 2015; 6(6): 252-263 [PMID: 26677438 DOI: 10.5306/wjco.v6.i6.252] |
|---|---|
| URL: | https://www.wjgnet.com/2218-4333/full/v6/i6/252.htm |
| Number | Citing Articles |
| 1 |
Alexus Acton, William J. Placzek. Myeloid Cell Leukemia 1 Small Molecule Inhibitor S63845 Synergizes with Cisplatin in Triple-Negative Breast Cancer. Cancers 2023; 15(18): 4481 doi: 10.3390/cancers15184481
|
| 2 |
Richard D. A. Wilkinson, Roberta E. Burden, Sara H. McDowell, Darragh G. McArt, Stephen McQuaid, Victoria Bingham, Rich Williams, Órla T. Cox, Rosemary O’Connor, Nuala McCabe, Richard D. Kennedy, Niamh E. Buckley, Christopher J. Scott. A Novel Role for Cathepsin S as a Potential Biomarker in Triple Negative Breast Cancer. Journal of Oncology 2019; 2019: 1 doi: 10.1155/2019/3980273
|
| 3 |
Soo-Yeon Hwang, Seojeong Park, Youngjoo Kwon. Recent therapeutic trends and promising targets in triple negative breast cancer. Pharmacology & Therapeutics 2019; 199: 30 doi: 10.1016/j.pharmthera.2019.02.006
|
| 4 |
Ramya Ambur Sankaranarayanan, Alexandru Florea, Susanne Allekotte, Andreas T. J. Vogg, Jochen Maurer, Laura Schäfer, Carsten Bolm, Steven Terhorst, Arno Classen, Matthias Bauwens, Agnieszka Morgenroth, Felix M. Mottaghy. PARP targeted Auger emitter therapy with [125I]PARPi-01 for triple-negative breast cancer. EJNMMI Research 2022; 12(1) doi: 10.1186/s13550-022-00932-9
|
| 5 |
R. M. Paltuev. Biological rationale for patient-specific treatment of breast cancer. Analysis of new data for breast cancer. Tumors of female reproductive system 2020; 15(4): 30 doi: 10.17650/1994-4098-2019-15-4-30-49
|
| 6 |
Cláudia Lopes, Paulina Piairo, Alexandre Chícharo, Sara Abalde-Cela, Liliana R. Pires, Patrícia Corredeira, Patrícia Alves, Laura Muinelo-Romay, Luís Costa, Lorena Diéguez. HER2 Expression in Circulating Tumour Cells Isolated from Metastatic Breast Cancer Patients Using a Size-Based Microfluidic Device. Cancers 2021; 13(17): 4446 doi: 10.3390/cancers13174446
|
| 7 |
Bowen Li, Jianwu Tian, Xin Xie, Fu Zhang, Chongzhi Wu, Yi Shan, Guobin Qi, Wentao Song, Yuan Ping, Bin Liu. Overcoming ROS Resistance of Photodynamic Therapy with Self‐Assembled Nano‐Prodrugs for Efficient Triple‐Negative Breast Cancer. Advanced Functional Materials 2024; 34(4) doi: 10.1002/adfm.202309524
|
| 8 |
Mansi Shah, Ryan Cardenas, Belinda Wang, Jenny Persson, Nigel P. Mongan, Anna Grabowska, Cinzia Allegrucci. HOXC8 regulates self-renewal, differentiation and transformation of breast cancer stem cells. Molecular Cancer 2017; 16(1) doi: 10.1186/s12943-017-0605-z
|
| 9 |
Shahensha Shaik, Ha’reanna Campbell, Christopher Williams. NURR1 Is Differentially Expressed in Breast Cancer According to Patient Racial Identity and Tumor Subtype. BioMedInformatics 2022; 2(4): 680 doi: 10.3390/biomedinformatics2040045
|
| 10 |
Eman F. Abdelhaleem, Mohammed K. Abdelhameid, Asmaa E. Kassab, Manal M. Kandeel. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7. European Journal of Medicinal Chemistry 2018; 143: 1807 doi: 10.1016/j.ejmech.2017.10.075
|
| 11 |
Fabiola Giudici, Elisabetta Petracci, Oriana Nanni, Cristina Bottin, Maurizio Pinamonti, Fabrizio Zanconati, Bruna Scaggiante, Aamir Ahmad. Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis. PLOS ONE 2019; 14(6): e0218030 doi: 10.1371/journal.pone.0218030
|
| 12 |
Ruihao Li, Xiaochun Hu, Fangjian Shang, Wenjing Wu, Haijun Zhang, Yixuan Wang, Jiawei Pan, Shuo Shi, Chunyan Dong. Treatment of triple negative breast cancer by near infrared light triggered mild-temperature photothermal therapy combined with oxygen-independent cytotoxic free radicals. Acta Biomaterialia 2022; 148: 218 doi: 10.1016/j.actbio.2022.06.011
|
| 13 |
Yu Zhou, Yingqi Che, Zhongze Fu, Henan Zhang, Huiyu Wu. Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy. Frontiers in Public Health 2022; 10 doi: 10.3389/fpubh.2022.902378
|
| 14 |
Jessica Iorio, Icro Meattini, Simonetta Bianchi, Marco Bernini, Virginia Maragna, Luca Dominici, Donato Casella, Vania Vezzosi, Lorenzo Orzalesi, Jacopo Nori, Lorenzo Livi, Annarosa Arcangeli, Elena Lastraioli. hERG1 channel expression associates with molecular subtypes and prognosis in breast cancer. Cancer Cell International 2018; 18(1) doi: 10.1186/s12935-018-0592-1
|
| 15 |
Hamsa D, Praveen Kumar K, Shanmughavel P, Poornima A, Sumathi S. Screening of key modulatory genes by Degalactotigonin in Triple Negative Breast Cancer cells – An in silico approach. Meta Gene 2020; 26: 100799 doi: 10.1016/j.mgene.2020.100799
|
| 16 |
Elizabeth A. Wilson, Nahid Sultana, Khyati N. Shah, Howard L. Elford, Jesika S. Faridi. Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer. Molecular Cancer Therapeutics 2021; 20(4): 655 doi: 10.1158/1535-7163.MCT-20-0373
|
| 17 |
Chun-Yu Liu, Tzu-Ting Huang, Pei-Yi Chu, Chun-Teng Huang, Chia-Han Lee, Wan-Lun Wang, Ka-Yi Lau, Wen-Chun Tsai, Tzu-I Chao, Jung-Chen Su, Ming-Huang Chen, Chung-Wai Shiau, Ling-Ming Tseng, Kuen-Feng Chen. The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells. Experimental & Molecular Medicine 2017; 49(8): e366 doi: 10.1038/emm.2017.114
|
| 18 |
Shuang Hao, Zhi-Xian He, Ke-Da Yu, Wen-Tao Yang, Zhi-Min Shao. New insights into the prognostic value of Ki-67 labeling index in patients with triple-negative breast cancer. Oncotarget 2016; 7(17): 24824 doi: 10.18632/oncotarget.8531
|
| 19 |
Ozge Saatci, Aysegul Kaymak, Umar Raza, Pelin G. Ersan, Ozge Akbulut, Carolyn E. Banister, Vitali Sikirzhytski, Unal Metin Tokat, Gamze Aykut, Suhail A. Ansari, Hayriye Tatli Dogan, Mehmet Dogan, Pouria Jandaghi, Aynur Isik, Fatma Gundogdu, Kemal Kosemehmetoglu, Omer Dizdar, Sercan Aksoy, Aytekin Akyol, Aysegul Uner, Phillip J. Buckhaults, Yasser Riazalhosseini, Ozgur Sahin. Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nature Communications 2020; 11(1) doi: 10.1038/s41467-020-16199-4
|
| 20 |
Janis Stiefel, Michael Baßler, Jörn Wittek, Christian Freese. Automated Immunomagnetic Enrichment and Optomicrofluidic Detection to Isolate Breast Cancer Cells: A Proof-of-Concept towards PoC Therapeutic Decision-Making. Magnetochemistry 2022; 8(9): 99 doi: 10.3390/magnetochemistry8090099
|
| 21 |
Mellisa Renteria, Ofek Belkin, David Jang, Justin Aickareth, Muaz Bhalli, Jun Zhang. CmPn signaling networks in the tumorigenesis of breast cancer. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.1013892
|
| 22 |
Rhafaela Lima Causin, Mariana Regatieri Polezi, Ana Julia Aguiar de Freitas, Stéphanie Calfa, Wanessa Fernanda Altei, Júlia Oliveira Dias, Ana Carolina Laus, Danielle Pessôa-Pereira, Tatiana Takahasi Komoto, Adriane Feijó Evangelista, Cristiano de Pádua Souza, Rui Manuel Reis, Marcia Maria Chiquitelli Marques. EV-miRNAs from breast cancer patients of plasma as potential prognostic biomarkers of disease recurrence. Heliyon 2024; 10(14): e33933 doi: 10.1016/j.heliyon.2024.e33933
|
| 23 |
Teng Pan, Tingting Mao, Haiyan Yang, Haiyu Wang, Yadong Wang. Silencing of TGIF sensitizes MDA‑MB‑231 human breast cancer cells to cisplatin‑induced apoptosis. Experimental and Therapeutic Medicine 2018; doi: 10.3892/etm.2018.5780
|
| 24 |
Elisa Roda, Fabrizio De Luca, Carmine Di Iorio, Daniela Ratto, Stella Siciliani, Beatrice Ferrari, Filippo Cobelli, Giuseppina Borsci, Erica Cecilia Priori, Silvia Chinosi, Andrea Ronchi, Renato Franco, Raffaele Di Francia, Massimiliano Berretta, Carlo Alessandro Locatelli, Andrej Gregori, Elena Savino, Maria Grazia Bottone, Paola Rossi. Novel Medicinal Mushroom Blend as a Promising Supplement in Integrative Oncology: A Multi-Tiered Study using 4T1 Triple-Negative Mouse Breast Cancer Model. International Journal of Molecular Sciences 2020; 21(10): 3479 doi: 10.3390/ijms21103479
|
| 25 |
Kamali Chakkaravarthi, Rajashree Ramesh, Thirunavukkarasu Palaniyandi, Gomathy Baskar, Sandhiya Viswanathan, Mugip Rahaman Abdul Wahab, Hemapreethi Surendran, Maddaly Ravi, Asha Sivaji. Prospectives of mirna gene signaling pathway in triple-negative breast cancer. Pathology - Research and Practice 2023; 248: 154658 doi: 10.1016/j.prp.2023.154658
|
| 26 |
Natalia Gurvits, Eliisa Löyttyniemi, Marjukka Nykänen, Teijo Kuopio, Pauliina Kronqvist, Kati Talvinen. Separase is a marker for prognosis and mitotic activity in breast cancer. British Journal of Cancer 2017; 117(9): 1383 doi: 10.1038/bjc.2017.301
|
| 27 |
Junping Liu, Wei Zhang, Wanxia Cai, Yumei Chen, Xiaozhong Cai, Donge Tang, Min Tang, Yong Dai. Multi-Omics Analyses Revealed GOLT1B as a Potential Prognostic Gene in Breast Cancer Probably Regulating the Immune Microenvironment. Frontiers in Oncology 2022; 11 doi: 10.3389/fonc.2021.805273
|
| 28 |
Muhseena N. Katheeja, Shankar Prasad Das, Ranajit Das, Suparna Laha. BRCA1 interactors, RAD50 and BRIP1, as prognostic markers for triple-negative breast cancer severity. Frontiers in Genetics 2023; 14 doi: 10.3389/fgene.2023.1035052
|
| 29 |
Qiuhong Wang, Sheng Gao, Haibo Li, Mingming Lv, Cheng Lu. Long noncoding RNAs (lncRNAs) in triple negative breast cancer. Journal of Cellular Physiology 2017; 232(12): 3226 doi: 10.1002/jcp.25830
|
| 30 |
Yaming Li, Ning Zhang, Hanwen Zhang, Qifeng Yang. Comparative prognostic analysis for triple-negative breast cancer with metaplastic and invasive ductal carcinoma. Journal of Clinical Pathology 2019; 72(6): 418 doi: 10.1136/jclinpath-2018-205544
|
| 31 |
Shuxun Shi, Cong Xu, Xiaonan Fang, Yonghuan Zhang, Hua Li, Wujun Wen, Guiwen Yang. Expression profile of Toll‑like receptors in human breast cancer. Molecular Medicine Reports 2019; doi: 10.3892/mmr.2019.10853
|
| 32 |
Humaira Khan, Muhammad Raza Shah, Jiri Barek, Muhammad Imran Malik. Cancer biomarkers and their biosensors: A comprehensive review. TrAC Trends in Analytical Chemistry 2023; 158: 116813 doi: 10.1016/j.trac.2022.116813
|
| 33 |
Elisa Roda, Fabrizio De Luca, Carlo Alessandro Locatelli, Daniela Ratto, Carmine Di Iorio, Elena Savino, Maria Grazia Bottone, Paola Rossi. From a Medicinal Mushroom Blend a Direct Anticancer Effect on Triple-Negative Breast Cancer: A Preclinical Study on Lung Metastases. Molecules 2020; 25(22): 5400 doi: 10.3390/molecules25225400
|
| 34 |
Marissa Howard, James Erickson, Zachary Cuba, Shawn Kim, Weidong Zhou, Purva Gade, Rachel Carter, Kelsey Mitchell, Heather Branscome, Daivik Siddhi, Fatimah Alanazi, Yuriy Kim, Robyn P. Araujo, Amanda Haymond, Alessandra Luchini, Fatah Kashanchi, Lance A. Liotta. A secretory form of Parkin‐independent mitophagy contributes to the repertoire of extracellular vesicles released into the tumour interstitial fluid in vivo. Journal of Extracellular Vesicles 2022; 11(7) doi: 10.1002/jev2.12244
|
| 35 |
G.I. Uscanga-Perales, S.K. Santuario-Facio, R. Ortiz-López. Triple negative breast cancer: Deciphering the biology and heterogeneity. Medicina Universitaria 2016; 18(71): 105 doi: 10.1016/j.rmu.2016.05.007
|
| 36 |
Guangcun Cheng, Xuemei Fan, Mingang Hao, Jinglong Wang, Xiaoming Zhou, Xueqing Sun. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer. Molecular Cancer 2016; 15(1) doi: 10.1186/s12943-016-0515-5
|
| 37 |
Tamás Mezei, Melinda Hajdu, Gábor Czigléczki, Gábor Lotz, Judit Kocsis, Janina Kulka, Anna Horváth. Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: a case report and literature review. BMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-07114-7
|
| 38 |
Bruno Gil, Meysam Keshavarz, Dominic Wales, Ara Darzi, Eric Yeatman. Orthogonal Surface‐Enhanced Raman Scattering/Field‐Effect Transistor Detection of Breast and Colorectal Cancer‐Derived Exosomes using Graphene as a Tag‐Free Diagnostic Template. Advanced NanoBiomed Research 2023; 3(11) doi: 10.1002/anbr.202300055
|
| 39 |
Yuxin Xie, Qiheng Gou, Qianqian Wang, Xiaorong Zhong, Hong Zheng. The role of BRCA status on prognosis in patients with triple-negative breast cancer. Oncotarget 2017; 8(50): 87151 doi: 10.18632/oncotarget.19895
|
| 40 |
Jessica Catarine Frutuoso do Nascimento, Eduardo Isidoro Carneiro Beltrão, Cíntia Renata Costa Rocha. High FUT3 expression is a marker of lower overall survival of breast cancer patients. Glycoconjugate Journal 2020; 37(2): 263 doi: 10.1007/s10719-020-09914-2
|
| 41 |
Rui Hong, Hongyu Sun, Dujuan Li, Weihuang Yang, Kai Fan, Chaoran Liu, Linxi Dong, Gaofeng Wang. A Review of Biosensors for Detecting Tumor Markers in Breast Cancer. Life 2022; 12(3): 342 doi: 10.3390/life12030342
|
| 42 |
Chen-Yun Wang, Cing-Hong Wang, Ru-Tsun Mai, Ting-Wen Chen, Chia-Wei Li, Chi-Hong Chao. Mutant p53-microRNA-200c-ZEB2-Axis-Induced CPT1C Elevation Contributes to Metabolic Reprogramming and Tumor Progression in Basal-Like Breast Cancers. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.940402
|
| 43 |
Abhilasha Sinha, Bibbin T. Paul, Lisa M. Sullivan, Hillary Sims, Ahmed El Bastawisy, Hend F. Yousef, Abdel-Rahman N. Zekri, Abeer A. Bahnassy, Wael M. ElShamy. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions. Oncotarget 2017; 8(6): 10114 doi: 10.18632/oncotarget.14357
|
| 44 |
Andrea Angius, Paolo Cossu-Rocca, Caterina Arru, Maria Rosaria Muroni, Vincenzo Rallo, Ciriaco Carru, Paolo Uva, Giovanna Pira, Sandra Orrù, Maria Rosaria De Miglio. Modulatory Role of microRNAs in Triple Negative Breast Cancer with Basal-Like Phenotype. Cancers 2020; 12(11): 3298 doi: 10.3390/cancers12113298
|
| 45 |
Longquan Lou, Ziyi Yu, Yue Wang, Shui Wang, Yi Zhao. c‐Src inhibitor selectively inhibits triple‐negative breast cancer overexpressed Vimentin in vitro and in vivo. Cancer Science 2018; 109(5): 1648 doi: 10.1111/cas.13572
|
| 46 |
Eunah Cho, Yeo-Jung Kwon, Dong-Jin Ye, Hyoung-Seok Baek, Tae-Uk Kwon, Hyung-Kyoon Choi, Young-Jin Chun. G0/G1 Switch 2 Induces Cell Survival and Metastasis through Integrin-Mediated Signal Transduction in Human Invasive Breast Cancer Cells. Biomolecules & Therapeutics 2019; 27(6): 591 doi: 10.4062/biomolther.2019.063
|
| 47 |
Insaf Fkih M’hamed, Maud Privat, Mounir Trimeche, Frédérique Penault-Llorca, Yves-Jean Bignon, Abderraouf Kenani. miR-10b, miR-26a, miR-146a And miR-153 Expression in Triple Negative Vs Non Triple Negative Breast Cancer: Potential Biomarkers. Pathology & Oncology Research 2017; 23(4): 815 doi: 10.1007/s12253-017-0188-4
|
| 48 |
Gil-Im Mun, Eun Choi, Hee Jin, Seul-Ki Choi, Hanhee Lee, Seoyoung Kim, Junghyun Kim, Chaerin Kang, Hye Lim Oh, Hae-June Lee, Dae-Ro Ahn, Yun-Sil Lee. Phosphorylation of BRCA1 at serine 1387 plays a critical role in cathepsin S-mediated radiation resistance via BRCA1 degradation and BCL2 stabilization. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2025; 1871(1): 167523 doi: 10.1016/j.bbadis.2024.167523
|
| 49 |
Su-Hyeong Kim, Eun-Ryeong Hahm, Julie A. Arlotti, Suman K. Samanta, Michelle B. Moura, Stephen H. Thorne, Yongli Shuai, Carolyn J. Anderson, Alexander G. White, Anna Lokshin, Joomin Lee, Shivendra V. Singh. Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown. Breast Cancer Research and Treatment 2016; 157(1): 41 doi: 10.1007/s10549-016-3795-y
|
| 50 |
Ella Markalunas, David Arnold, Avery Funkhouser, Julie Martin, Michael Shtutman, W. Edenfield, Anna Blenda. Correlation Analysis of Genetic Mutations and Galectin Levels in Breast Cancer Patients. Genes 2024; 15(6): 818 doi: 10.3390/genes15060818
|
| 51 |
Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas, Octavio Burgués, Cristina Hernando, María Teresa Martínez, Federico Rojo, Begoña Bermejo, Marta Tapia, Juan Antonio Carbonell-Asins, Carlos Javier Peña, Ana Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pilar Eroles. MiRNA-449 family is epigenetically repressed and sensitizes to doxorubicin through ACSL4 downregulation in triple-negative breast cancer. Cell Death Discovery 2024; 10(1) doi: 10.1038/s41420-024-02128-7
|
| 52 |
Nilofer Shaikh, Sanket Bapat, Muthukumarasamy Karthikeyan, Renu Vyas. A Review on Computational Analysis of Big Data in Breast Cancer for Predicting Potential Biomarkers. Current Topics in Medicinal Chemistry 2022; 22(21): 1793 doi: 10.2174/1568026622666220907121942
|
| 53 |
Daniela Massihnia, Alessandro Perez, Viviana Bazan, Giuseppe Bronte, Marta Castiglia, Daniele Fanale, Nadia Barraco, Antonina Cangemi, Florinda Di Piazza, Valentina Calò, Sergio Rizzo, Giuseppe Cicero, Gianni Pantuso, Antonio Russo. A headlight on liquid biopsies: a challenging tool for breast cancer management. Tumor Biology 2016; 37(4): 4263 doi: 10.1007/s13277-016-4856-x
|
| 54 |
Eliana Noelia Alonso, María Julia Ferronato, María Eugenia Fermento, Norberto Ariel Gandini, Alejandro López Romero, Josefina Alejandra Guevara, María Marta Facchinetti, Alejandro Carlos Curino. Antitumoral and antimetastatic activity of Maitake D-Fraction in triple-negative breast cancer cells. Oncotarget 2018; 9(34): 23396 doi: 10.18632/oncotarget.25174
|
| 55 |
Katheeja Muhseena N, Sooraj Mathukkada, Shankar Prasad Das, Suparna Laha. The repair gene <em>BACH1</em> - a potential oncogene. Oncology Reviews 2021; 15(1) doi: 10.4081/oncol.2021.519
|
| 56 |
Abhishek Kanugo, Rupesh K. Gautam, Mohammad Amjad Kamal. Recent Advances of Nanotechnology in the Diagnosis and Therapy of Triple-
Negative Breast Cancer (TNBC). Current Pharmaceutical Biotechnology 2022; 23(13): 1581 doi: 10.2174/1389201023666211230113658
|
| 57 |
Charu Kothari, Mazid Abiodoun Osseni, Lynda Agbo, Geneviève Ouellette, Maxime Déraspe, François Laviolette, Jacques Corbeil, Jean-Philippe Lambert, Caroline Diorio, Francine Durocher. Machine learning analysis identifies genes differentiating triple negative breast cancers. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-67525-1
|
| 58 |
Pei-Jou Chua, Suet-Hui Ow, Cheng-Teng Ng, Wan-Hong Huang, Jie-Ting Low, Puay Hoon Tan, Michael W.Y. Chan, Boon-Huat Bay. Peroxiredoxin 3 regulates breast cancer progression via ERK-mediated MMP-1 expression. Cancer Cell International 2024; 24(1) doi: 10.1186/s12935-024-03248-x
|
| 59 |
Ashutosh Gupta, Kumar Nishchaya, Moumita Saha, Gaurisha Alias Resha Ramnath Naik, Sarika Yadav, Shreya Srivastava, Amrita Arup Roy, Sudheer Moorkoth, Srinivas Mutalik, Namdev Dhas. Recent advancements in nanoconstructs for the theranostics applications for triple negative breast cancer. Journal of Drug Delivery Science and Technology 2024; 93: 105401 doi: 10.1016/j.jddst.2024.105401
|
| 60 |
Nihad Al-Othman, Mamoun Ahram, Moath Alqaraleh. Role of androgen and microRNA in triple-negative breast cancer. Breast Disease 2020; 39(1): 15 doi: 10.3233/BD-190416
|
| 61 |
Bayan Zoatier, Metin Yildirim, Mehmet Abdullah Alagoz, Derya Yetkin, Burcin Turkmenoglu, Serdar Burmaoglu, Oztekin Algul. N-(benzazol-2-yl)-2-substituted phenylacetamide derivatives: Design, synthesis and biological evaluation against MCF7 breast cancer cell line. Journal of Molecular Structure 2023; 1285: 135513 doi: 10.1016/j.molstruc.2023.135513
|
| 62 |
Michaela Aubele, Manfred Schmitt, Rudolf Napieralski, Stefan Paepke, Johannes Ettl, Magdalena Absmaier, Viktor Magdolen, John Martens, John A. Foekens, Olaf G. Wilhelm, Marion Kiechle. The Predictive Value ofPITX2DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges. Disease Markers 2017; 2017: 1 doi: 10.1155/2017/4934608
|
| 63 |
I. Roxanis, R. Colling, C. Kartsonaki, A. R. Green, E A. Rakha. The significance of tumour microarchitectural features in breast cancer prognosis: a digital image analysis. Breast Cancer Research 2018; 20(1) doi: 10.1186/s13058-018-0934-x
|
| 64 |
A-In Kim, Ji Hoon Oh, Je-Yoel Cho. QSOX2 Upregulated in triple-negative breast cancer exacerbates patient prognosis by stabilizing integrin β1. Heliyon 2024; 10(6): e27148 doi: 10.1016/j.heliyon.2024.e27148
|
| 65 |
Monica J. Engstrøm, Marit Valla, Anna M. Bofin. Basal markers and prognosis in luminal breast cancer. Breast Cancer Research and Treatment 2017; 163(2): 207 doi: 10.1007/s10549-017-4182-z
|
| 66 |
Siliang Xue, Lang He, Xiao Zhang, Jin Zhou, Fanghua Li, Xiaoshan Wang. Expression of Jagged1/Notch3 Signaling Pathway and their Relationship with the Tumor Angiogenesis in TNBC. Archives of Medical Research 2017; 48(2): 169 doi: 10.1016/j.arcmed.2017.03.014
|
| 67 |
Feng Yang, Michaela Aubele, Axel Walch, Eva Gross, Rudolf Napieralski, Shuo Zhao, Nancy Ahmed, Marion Kiechle, Ute Reuning, Julia Dorn, Fred Sweep, Viktor Magdolen, Manfred Schmitt. Tissue kallikrein-related peptidase 4 (KLK4), a novel biomarker in triple-negative breast cancer. Biological Chemistry 2017; 398(10): 1151 doi: 10.1515/hsz-2017-0122
|
| 68 |
Miseon Lee, In Ah Park, Sun-Hee Heo, Young-Ae Kim, Gyungyub Gong, Hee Jin Lee. Association between p53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Journal of Pathology and Translational Medicine 2019; 53(3): 180 doi: 10.4132/jptm.2019.02.08
|
| 69 |
Swaroop Kumar Pandey, Mradula Parul, Manikandan Santhanam. Aptamer-guided Selective Delivery of Therapeutics to Breast Cancer Cells
Expressing Specific Biomarkers. Current Cancer Therapy Reviews 2024; 20(5): 434 doi: 10.2174/1573394719666230911113126
|
| 70 |
John J. Bassett, Alice H.L. Bong, Ellen K. Janke, Mélanie Robitaille, Sarah J. Roberts-Thomson, Amelia A. Peters, Gregory R. Monteith. Assessment of cytosolic free calcium changes during ceramide-induced cell death in MDA-MB-231 breast cancer cells expressing the calcium sensor GCaMP6m. Cell Calcium 2018; 72: 39 doi: 10.1016/j.ceca.2018.02.003
|
| 71 |
Yonglin Zhao, Xing Wei, Jia Li, Yan Diao, Changyou Shan, Weimiao Li, Shuqun Zhang, Fei Wu. High Level of GMFG Correlated to Poor Clinical Outcome and Promoted Cell Migration and Invasion through EMT Pathway in Triple-Negative Breast Cancer. Genes 2023; 14(6): 1157 doi: 10.3390/genes14061157
|
| 72 |
Xiaolu Yang, Tiantian Tang, Tao Zhou. Clinicopathological characteristics and prognosis of metaplastic breast cancer versus triple-negative invasive ductal carcinoma: a retrospective analysis. World Journal of Surgical Oncology 2023; 21(1) doi: 10.1186/s12957-023-03261-w
|
| 73 |
Touko Inao, Yuichi Iida, Tamami Moritani, Tamio Okimoto, Ryosuke Tanino, Hitoshi Kotani, Mamoru Harada. Bcl-2 inhibition sensitizes triple-negative human breast cancer cells to doxorubicin. Oncotarget 2018; 9(39): 25545 doi: 10.18632/oncotarget.25370
|
| 74 |
Guochen Zhang, Junlan Wang, Ruilin Zheng, Beibei Song, Li Huang, Yujiang Liu, Yating Hao, Xiangdong Bai. MiR-133 Targets YES1 and Inhibits the Growth of Triple-Negative Breast Cancer Cells. Technology in Cancer Research & Treatment 2020; 19 doi: 10.1177/1533033820927011
|
| 75 |
Xuan-Yu Mao, Jesus Perez-Losada, Mar Abad, Marta Rodríguez-González, Cesar A Rodríguez, Jian-Hua Mao, Hang Chang. iCEMIGE: Integration of CEll-morphometrics, MIcrobiome, and GEne biomarker signatures for risk stratification in breast cancers. World Journal of Clinical Oncology 2022; 13(7): 616-629 doi: 10.5306/wjco.v13.i7.616
|
| 76 |
Pamungkas Bagus Satriyo, Oluwaseun Adebayo Bamodu, Jia-Hong Chen, Teguh Aryandono, Sofia Mubarika Haryana, Chi-Tai Yeh, Tsu-Yi Chao. Cadherin 11 Inhibition Downregulates β-catenin, Deactivates the Canonical WNT Signalling Pathway and Suppresses the Cancer Stem Cell-Like Phenotype of Triple Negative Breast Cancer. Journal of Clinical Medicine 2019; 8(2): 148 doi: 10.3390/jcm8020148
|
| 77 |
Ishita Gupta, Rasha M. Sareyeldin, Israa Al-Hashimi, Hamda A. Al-Thawadi, Halema Al Farsi, Semir Vranic, Ala-Eddin Al Moustafa. Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity. Cancers 2019; 11(3): 363 doi: 10.3390/cancers11030363
|
| 78 |
Halima Alsamri, Hussain El Hasasna, Yusra Al Dhaheri, Ali H. Eid, Samir Attoub, Rabah Iratni. Carnosol, a Natural Polyphenol, Inhibits Migration, Metastasis, and Tumor Growth of Breast Cancer via a ROS-Dependent Proteasome Degradation of STAT3. Frontiers in Oncology 2019; 9 doi: 10.3389/fonc.2019.00743
|
| 79 |
Bin Xiong, Xuefeng Lei, Lei Zhang, Jia Fu. The clinical significance and biological function of olfactomedin 4 in triple negative breast cancer. Biomedicine & Pharmacotherapy 2017; 86: 67 doi: 10.1016/j.biopha.2016.11.081
|
| 80 |
Ishita Gupta, Balsam Rizeq, Semir Vranic, Ala-Eddin Al Moustafa, Halema Al Farsi. Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets. International Journal of Molecular Sciences 2020; 21(18): 6750 doi: 10.3390/ijms21186750
|
| 81 |
Dana M. Zaher, Iman M. Talaat, Amal Hussein, Mahmood Y. Hachim, Hany A. Omar. Differential expression of pyruvate dehydrogenase E1A and its inactive phosphorylated form among breast cancer subtypes. Life Sciences 2021; 284: 119885 doi: 10.1016/j.lfs.2021.119885
|
| 82 |
Anindita De, Sonam Patel, K. Gowthamarajan. Functional Smart Nanomaterials and Their Theranostics Approaches. Smart Nanomaterials Technology 2024; : 119 doi: 10.1007/978-981-99-6597-7_5
|
| 83 |
Binbin Tan, Ying Zhang, Tiantian Zhang, Jinsong He, Xueying Luo, Xiqing Bian, Jianlin Wu, Chang Zou, Yangzhi Wang, Li Fu. Identifying potential serum biomarkers of breast cancer through targeted free fatty acid profiles screening based on a GC–MS platform. Biomedical Chromatography 2020; 34(10) doi: 10.1002/bmc.4922
|
| 84 |
Silvia Cecilia Pacheco-Velázquez, Juan Carlos Gallardo-Pérez, Daniel Díaz, Alhelí Adán-Ladrón de Guevara, Diana Xochiquetzal Robledo-Cadena, Emma Saavedra, Luz Ruiz-Godoy, Luis Roberto Jimenez-Hernández, Jesús Vargas-Barrón, José Luis Aguilar-Ponce, Sara Rodríguez-Enríquez. Heart myxoma develops oncogenic and metastatic phenotype. Journal of Cancer Research and Clinical Oncology 2019; 145(5): 1283 doi: 10.1007/s00432-019-02897-0
|
| 85 |
Elnaz Faghfuri, Mohsen Sagha, Amir Hossein Faghfouri. The Cytotoxicity Effect of Curcumin Loaded Folic Acid Conjugated-Nanoparticles on Breast Cancer Cells and Its Association with Inhibition of STAT3 Phosphorylation. Journal of Cluster Science 2022; 33(5): 2037 doi: 10.1007/s10876-021-02125-1
|
| 86 |
Felipe C. M. Zoppino, Martin E. Guerrero-Gimenez, Gisela N. Castro, Daniel R. Ciocca. Comprehensive transcriptomic analysis of heat shock proteins in the molecular subtypes of human breast cancer. BMC Cancer 2018; 18(1) doi: 10.1186/s12885-018-4621-1
|
| 87 |
Brianna J. McIntosh, Griffin G. Hartmann, Sean A. Yamada‐Hunter, Phillip Liu, Camille F. Williams, Julien Sage, Jennifer R. Cochran. An engineered interleukin‐11 decoy cytokine inhibits receptor signaling and proliferation in lung adenocarcinoma. Bioengineering & Translational Medicine 2023; 8(6) doi: 10.1002/btm2.10573
|
| 88 |
Fouzia Guestini, Katsuhiko Ono, Minoru Miyashita, Takanori Ishida, Noriaki Ohuchi, Saki Nakagawa, Hisashi Hirakawa, Kentaro Tamaki, Yasuyo Ohi, Yoshiaki Rai, Yasuaki Sagara, Hironobu Sasano, Keely May McNamara. Impact of Topoisomerase IIα, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment 2019; 173(2): 275 doi: 10.1007/s10549-018-4985-6
|
| 89 |
Aysha Alneyadi, Zohra Nausheen Nizami, Hanan E. Aburawi, Soleiman Hisaindee, Muhammad Nawaz, Samir Attoub, Gaber Ramadan, Nehla Benhalilou, Mazoun Al Azzani, Yassine Elmahi, Aysha Almeqbali, Khalid Muhammed, Ali H. Eid, Ranjit Vijayan, Rabah Iratni. Synthesis of New Chromene Derivatives Targeting Triple-Negative Breast Cancer Cells. Cancers 2023; 15(10): 2682 doi: 10.3390/cancers15102682
|
| 90 |
Zhen Li, Jian Dong, Tianning Zou, Chengzhi Du, Siyuan Li, Ceshi Chen, Rong Liu, Kunhua Wang. Dexamethasone induces docetaxel and cisplatin resistance partially through up-regulating Krüppel-like factor 5 in triple-negative breast cancer. Oncotarget 2017; 8(7): 11555 doi: 10.18632/oncotarget.14135
|
| 91 |
Peter Hofland. A Potential Biomarker for Treatment Response in Triple-negative Breast Cancer. Onco Zine - The International Oncology Network 2024; doi: 10.14229/onco.2024.09.13.021
|